Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Parkinson disease

Towards the era of biological biomarkers for Parkinson disease

Since its instigation in cancer research in the 1930s, the disease-staging concept has become a crucial tool in clinical research and medical practice. Two new papers have proposed biological staging and classification systems based on α-synuclein pathology for Parkinson disease and related conditions.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

References

  1. Greene, F. L. & Sobin, L. H. The staging of cancer: a retrospective and prospective appraisal. CA Cancer J. Clin. 58, 180–190 (2008).

    Article  PubMed  Google Scholar 

  2. Cardoso, F. et al. A statement of the MDS on biological definition, staging, and classification of Parkinson’s disease. Mov. Disord. https://doi.org/10.1002/mds.29683 (2023).

    Article  PubMed  Google Scholar 

  3. Höglinger, G. U. et al. A biological classification of Parkinson’s disease: the SynNeurGe research diagnostic criteria. Lancet Neurol. 23, 191–204 (2024).

    Article  PubMed  Google Scholar 

  4. Simuni, T. et al. A biological definition of neuronal α-synuclein disease: towards an integrated staging system for research. Lancet Neurol. 23, 178–190 (2024).

    Article  CAS  PubMed  Google Scholar 

  5. Siderowf, A. et al. Assessment of heterogeneity among participants in the Parkinson’s Progression Markers Initiative cohort using α-synuclein seed amplification: a cross-sectional study. Lancet Neurol. 22, 407–417 (2023).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Miki, Y. et al. Clinical availability of skin biopsy in the diagnosis of Parkinson’s disease. Neurosci. Lett. 469, 357–359 (2010).

    Article  CAS  PubMed  Google Scholar 

  7. Okuzumi, A. et al. Propagative α-synuclein seeds as serum biomarkers for synucleinopathies. Nat. Med. 29, 1448–1455 (2023).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Shahnawaz, M. et al. Discriminating α-synuclein strains in Parkinson’s disease and multiple system atrophy. Nature 578, 273–277 (2020).

    Article  CAS  ADS  PubMed  PubMed Central  Google Scholar 

  9. Couto, B., Marras, C. & Di Luca, D. G. α-Synuclein seed amplification in Parkinson’s disease. Lancet Neurol. 22, 983–984 (2023).

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Nobutaka Hattori.

Ethics declarations

Competing interests

The author declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hattori, N. Towards the era of biological biomarkers for Parkinson disease. Nat Rev Neurol (2024). https://doi.org/10.1038/s41582-024-00950-2

Download citation

  • Published:

  • DOI: https://doi.org/10.1038/s41582-024-00950-2

Search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research